Sector News

Abbott to spend $25bn on St Jude Medical

May 2, 2016
Life sciences

Abbott is buying medical device maker St Jude Medical in a deal worth around $25 billion.

Under the terms of the deal, St Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing a total consideration of around $85 per share. At an Abbott stock price of $43.93, this equates to a total transaction equity value of $25 billion.

According to the companies, the move will create “a premier medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure as well as a leading position in the high-growth neuromodulation market”.

With combined annual sales of approximately $8.7 billion, Abbott’s cardiovascular business and St. Jude Medical will hold the No. 1 or 2 positions across large and high-growth cardiovascular device markets and will compete in nearly every area of the market – with an aggregate market opportunity of $30 billion.

“Bringing together these two great companies will create a premier medical device business and immediately advance Abbott’s strategic and competitive position,” said Miles White, chairman and chief executive at Abbott. “The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for health care systems around the world.”

The acquisition is expected to be accretive to Abbott’s adjusted earnings per share in the first full year after closing and increasing thereafter, with around $0.21 of accretion in 2017 and $0.29 cents in 2018. The combination is also anticipated to result in annual pre-tax synergies of $500 million by 2020.

By Selina McKee

Source: Pharma Times

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.